News
03-17-2009, 03:25 AM
ExonHit Therapeutics (Alternext: ALEHT) reported the publication in Lancet Oncology of a study conducted by Institut Gustave Roussy, which describes the identification of a deregulated cell function in breast cancer through the analysis of alternative RNA splicing [1]. Study data demonstrate that exons are differently expressed in malignant and benign lesions, and alternative transcripts determine the molecular characteristics of breast malignancy.
More... (http://www.medicalnewstoday.com/articles/142441.php)
More... (http://www.medicalnewstoday.com/articles/142441.php)